Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Mainor, Candace
OXEL, NCT03487666: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease	Active, not recruiting	2	45	US	Nivolumab, Opdivo, Capecitabine, Xeloda	Georgetown University, Bristol-Myers Squibb	Triple Negative Breast Cancer	11/21	12/22
WI223281, NCT03535506: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery	Terminated	2	17	US	Palbociclib, Ibrance	Georgetown University, Pfizer	DCIS	12/23	12/23
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer	Recruiting	2	197	US	Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077	Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research	Breast Cancer, Triple Negative Breast Cancer	01/29	01/34
Ashai, Nadia
OASIS, NCT04720664: Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer	Terminated	2	11	US	SM-88	Georgetown University, Tyme, Inc	Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma	02/23	02/23
Bouker, Kerrie
No trials found
Bouker, Kerri
No trials found
Aguila, Frankie
No trials found